Formula I Anticancer Compound Targeting Hypoxic Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for aggressive and hypoxic tumors, face challenges in effectiveness due to resistance and limited survival rates, especially in cancers like pancreatic cancer, where existing therapies such as gemcitabine, docetaxel, and radiation show limited success.
Innovation Solution
A compound of Formula (I) or its pharmaceutically acceptable salt, administered alone or in combination with other anticancer agents, is used to treat various cancers, including those resistant to standard treatments, by targeting hypoxic tumors and potentially reversing treatment resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard cancer treatments (gemcitabine, docetaxel, radiation) are administered, then treatment is provided to cancer patients, but treatment resistance develops and survival rates remain low
Solution Approach 1:
The patent introduces a novel compound (Formula I) as an intermediary agent that specifically targets hypoxic tumor environments. This compound acts as a mediator between the therapeutic goal and the resistant tumor cells, overcoming treatment resistance through its unique mechanism of action in hypoxic conditions where standard therapies fail.
Solution Approach 2:
The invention changes the therapeutic parameter by targeting hypoxic conditions specifically. The compound is designed to exploit the hypoxic environment parameter of tumors, converting this adverse condition into a selective vulnerability that standard therapies cannot exploit, thereby overcoming treatment resistance.
2Reliability
If hypoxic conditions in tumors are present, then tumor progression and treatment resistance increase, but new therapeutic opportunities are created
Solution Approach 1:
The patent converts the harmful hypoxic condition into a beneficial therapeutic target. By designing a compound that specifically acts under hypoxic conditions, the invention transforms the previously adverse hypoxic environment into a selective vulnerability that enhances treatment effectiveness and improves survival rates.
3Reliability
If novel compounds targeting hypoxic tumors are developed, then treatment effectiveness improves, but drug development complexity increases
Solution Approach 1:
The compound exhibits local quality by having different activities in different environments. It is designed to be inactive or less active in normoxic conditions but becomes highly active in hypoxic tumor environments, allowing selective targeting without requiring overly complex molecular structures.
Data Source
AI summary
Provided herein are compounds, such as compounds for use in treating cancer. Also provided are methods of treating cancer, including treatment resistant cancer or cancer associated with a hypoxic tumor.